TG Therapeutics has the GF Score of 82, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes TG Therapeutics
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
TG Therapeutics (LTS:0VGI) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
TG Therapeutics GF Score Related Terms
LTS:0VGI vs HALO, KYMR, PCVX: GF Score Comparison
For the Biotechnology subindustry, TG Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's GF Score falls into.
TG Therapeutics (LTS:0VGI) has a GF Score of 82 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on TG Therapeutics and its competitors. This is 71% above median its historical median of 48.00. Over the past decade, TG Therapeutics' GF Score has ranged from 6.00 to 82.00.
Is TG Therapeutics' GF Score too high?
TG Therapeutics' current GF Score of 82 is 71% above median its 10-year median of 48.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 82.00. Overall, TG Therapeutics has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' GF Score compare to HALO and KYMR?
TG Therapeutics' GF Score of 82 can be compared against companies in the Biotechnology industry. Historically, TG Therapeutics' own GF Score has ranged from 6.00 to 82.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current GF Score is 82, which is 71% above median its own 10-year median of 48.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
TG Therapeutics (LTS:0VGI) has a current GF Score of 82. The stock's GF Value™ is $37.78, compared to a current price of $36.65 — trading 3% below its estimated fair value. The current GF Score is 82, which is 71% above median its 10-year median of 48.00. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For TG Therapeutics (LTS:0VGI), the current GF Score is 82 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (LTS:0VGI) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued.
The current stock price of $36.65 is trading 3% below its estimated GF Value™ of $37.78.
Key valuation signals for LTS:0VGI:
GF Score: 82 (71% above median its 10-year median of 48.00)
GF Value™: $37.78 vs. price of $36.65 (3% below fair value)
No single metric tells the full story. See the LTS:0VGI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score
Get the complete analysis for LTS:0VGI
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VGI has been successfully added to your 